Antenatal Corticosteroid Exposure in Late Preterm Infants: Clinical Considerations in Diabetic Mothers

For decades, the administration of antenatal corticosteroids (ACS) has been a cornerstone of obstetric care for pregnancies at risk of preterm birth. By accelerating fetal lung maturation, these medications significantly reduce the risk of respiratory distress syndrome (RDS) and neonatal mortality. However, as clinical practice evolves to include the “late preterm” window—defined as 34 weeks 0 days to 36 weeks 6 days of gestation—the application of ACS in mothers with diabetes has surfaced as a complex clinical challenge requiring careful management.

Understanding the Role of Antenatal Corticosteroids

Antenatal corticosteroids, typically betamethasone or dexamethasone, are administered to pregnant individuals at high risk of delivery before 34 weeks. The primary goal is to stimulate the production of surfactant in the fetal lungs. While the benefits of ACS in the early preterm period are well-established, their use in the late preterm period remains a subject of ongoing clinical investigation and debate, particularly regarding the delicate metabolic balance of mothers with pre-existing or gestational diabetes.

According to the American College of Obstetricians and Gynecologists (ACOG), the administration of a single rescue course of ACS may be considered for patients between 34 and 36 weeks of gestation who have not previously received corticosteroids and are at imminent risk of preterm birth. Yet, in diabetic patients, these steroids introduce a significant metabolic hurdle.

The Metabolic Challenge: Steroids and Maternal Glucose

Corticosteroids are well-known for their hyperglycemic effects. In a patient with diabetes, the administration of ACS can lead to a profound and sustained rise in maternal blood glucose levels. This phenomenon occurs because corticosteroids promote gluconeogenesis and decrease peripheral glucose uptake, effectively inducing a state of insulin resistance.

For a mother already managing diabetes, this spike poses two primary risks:

• Maternal Ketoacidosis: Rapidly rising glucose levels increase the risk of diabetic ketoacidosis (DKA), a medical emergency that can be life-threatening for both mother and fetus.
• Neonatal Hypoglycemia: When maternal blood glucose is elevated, the fetus produces increased amounts of insulin to compensate. Upon delivery, the sudden removal of the high-glucose maternal environment, coupled with the neonate’s hyperinsulinemia, often results in severe neonatal hypoglycemia.

Clinical Management Strategies

Managing the intersection of ACS exposure and maternal diabetes requires a multidisciplinary approach involving obstetricians, maternal-fetal medicine specialists, and endocrinologists. Evidence-based strategies to mitigate these risks include:

Intensified Glucose Monitoring

When ACS therapy is initiated, patients should undergo rigorous blood glucose monitoring, often increasing to every 1–2 hours. This allows clinicians to identify hyperglycemic trends immediately and intervene before levels reach critical thresholds.

Adjusting Insulin Protocols

Standard insulin regimens are rarely sufficient during the 48-hour window following corticosteroid administration. Many clinical protocols suggest the initiation of a temporary continuous intravenous insulin infusion to maintain euglycemia. This approach provides the flexibility needed to counteract the unpredictable, steroid-induced fluctuations in blood sugar.

Timing of Delivery

Clinicians must weigh the respiratory benefits of ACS against the metabolic risks. If the risk of preterm delivery is not imminent, providers often prioritize stabilizing maternal glucose levels before proceeding with elective or semi-urgent deliveries to minimize the risk of neonatal complications.

Key Takeaways for Clinical Practice

• Benefit-Risk Assessment: The decision to administer ACS in late preterm pregnancies must be individualized, particularly for diabetic patients.
• Metabolic Vigilance: Steroids induce significant insulin resistance; clinicians must anticipate and proactively manage maternal hyperglycemia.
• Neonatal Preparedness: Expectant management of the newborn should include early screening for hypoglycemia, as the risk is heightened following maternal steroid exposure.
• Multidisciplinary Care: Coordinating with diabetes educators and endocrinology teams is essential to ensure safe glycemic control throughout the hospital stay.

Conclusion

While antenatal corticosteroids remain a vital tool in modern obstetrics, their use in the late preterm period for diabetic mothers demands a high degree of clinical precision. By recognizing the powerful hyperglycemic effects of these medications and implementing aggressive, real-time glucose management protocols, healthcare providers can successfully navigate these challenges. As research continues to refine these guidelines, the ultimate goal remains the same: balancing the respiratory health of the infant with the metabolic safety of the mother.

Disclaimer: This article is for educational purposes and does not constitute medical advice. Always consult with your healthcare provider for clinical decision-making regarding pregnancy and diabetes management.